塞来昔布
医学
骨关节炎
随机对照试验
可视模拟标度
氟比洛芬
麻醉
沃马克
临床试验
生活质量(医疗保健)
口服
不利影响
内科学
布洛芬
外科
疼痛评分
患者满意度
止痛药
作者
Kaibo Sun,Min Pu,Huaixian Zhang,Liangtao Bai,Xiaoxiao Wu,Ling Fan,Qinsheng Hu
出处
期刊:Rheumatology
[Oxford University Press]
日期:2026-09-01
卷期号:65 (9): keag488-
标识
DOI:10.1093/rheumatology/keag488
摘要
OBJECTIVES: Rapid symptom control may facilitate earlier mobility and self-management in symptomatic knee OA (KOA), but evidence for combining oral and topical NSAIDs remains limited. This study aimed to determine whether adding a topical flurbiprofen patch to oral celecoxib provides greater short-term improvements in pain, physical function, quality of life and patient global assessment (PGA) than oral celecoxib alone in patients with symptomatic KOA. METHODS: In this open-label randomized controlled trial conducted at a tertiary academic hospital from January 2024 to March 2025, 90 patients with chronic inflammatory symptomatic KOA were randomized 1:1 to receive either oral celecoxib 200 mg once daily or celecoxib plus topical flurbiprofen patch twice daily. Outcomes were assessed at baseline and on days 3, 7 and 14. Primary outcomes were pain severity by visual analogue scale (VAS) and functional impairment by WOMAC. Secondary outcomes included quality of life by SF-36 and PGA. RESULTS: Eighty-nine patients completed the study (45 celecoxib; 44 combination therapy). Baseline characteristics were comparable between the groups. Compared with celecoxib alone, combination therapy produced greater early pain relief, with larger VAS reductions on day 3 (3.4 ± 0.9 vs 2.0 ± 0.8, P < 0.01) and day 7 (3.9 ± 1.0 vs 3.3 ± 1.0, P = 0.02), but not day 14. WOMAC improvement was greater in the combination group on days 3, 7 and 14 (all P < 0.01). At day 14, SF-36 health domain scores and PGA ratings were also higher with combination therapy. CONCLUSIONS: Adding topical flurbiprofen patch to oral celecoxib provided faster early improvement in pain and function and better short-term patient-reported outcomes in symptomatic KOA. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR1800014584.
科研通智能强力驱动
Strongly Powered by AbleSci AI